{"entity":{"id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","aka":[],"tldr":"A phase 2 trial of TCMCB07 in colorectal cancer, run by Endevica Bio, now recruiting.","summary":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy is a phase 2 interventional study registered as NCT06937177 by Endevica Bio, with 120 participants planned, started 2025-04-28 and due to reach its primary completion in 2027-10. Interventions recorded: TCMCB07 and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06937177","url":"https://clinicaltrials.gov/study/NCT06937177"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06937177","phase":"2","setting":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","sponsor":"Endevica Bio","enrolled":120,"outcomes":[]},"route":"/trials/nct06937177/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}